522 related articles for article (PubMed ID: 27217742)
1. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
2. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
[TBL] [Abstract][Full Text] [Related]
6. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
7. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
8. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
9. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
10. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
[TBL] [Abstract][Full Text] [Related]
11. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.
Muruganandan S; Jayaram L
Int J Chron Obstruct Pulmon Dis; 2015; 10():1179-89. PubMed ID: 26124657
[TBL] [Abstract][Full Text] [Related]
12. Effects of baseline symptom burden on treatment response in COPD.
Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
14. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
Kawachi S; Fujimoto K
Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
[No Abstract] [Full Text] [Related]
16. Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients.
Valipour A; Tamm M; Kociánová J; Bayer V; Sanzharovskaya M; Medvedchikov A; Haaksma-Herczegh M; Mucsi J; Fridlender Z; Toma C; Belevskiy A; Matula B; Šorli J
Int J Chron Obstruct Pulmon Dis; 2019; 14():2343-2354. PubMed ID: 31632003
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
18. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Ferguson GT; Feldman GJ; Hofbauer P; Hamilton A; Allen L; Korducki L; Sachs P
Int J Chron Obstruct Pulmon Dis; 2014; 9():629-45. PubMed ID: 24966672
[TBL] [Abstract][Full Text] [Related]
20. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
